Mayo Clinic Doctor Joins Advanced Medical Isotope Corporation's (ADMD) Medical Advisory Board
September 21 2017 - 7:22AM
Marketwired
Mayo Clinic Doctor Joins Advanced Medical Isotope Corporation's
(ADMD) Medical Advisory Board
RICHLAND, WA-(Marketwired - Sep 21, 2017) - Advanced Medical
Isotope Corporation (OTC PINK: ADMD), a late stage radiation
oncology focused medical device company strengthened its Medical
Advisory Board with the recent addition of Dr. Beau Toskich from
Mayo Clinic, who has been informally working with the Company's
advisory board for the last six months.
"We're pleased Dr. Toskich received the necessary permission
from Mayo Clinic to join our advisory board. An enthusiastic and
competent doctor, he, like others, sees the potential benefits of
RadioGel™ for treating cancer," stated Dr. Michael Korenko,
President and CEO of ADMD. "Our advisory board now has more than
135 years of combined experience in key disciplines, which provides
us with important guidance as we move forward on development and
commercialization plans."
Dr. Toskich is a Senior Associate Consultant in Vascular and
Interventional Radiology at Mayo Clinic's Florida Campus and
Assistant Professor, Vascular and Interventional Radiology, at the
University of Florida College of Medicine. He earned his M.D. from
Florida State University College of Medicine and completed a
fellowship in Vascular and Interventional Radiology at the
University of Florida. He is Board Certified in Diagnostic
Radiology, Vascular and Interventional Radiology, and a Nuclear
Regulatory Commission Authorized User.
About Advanced Medical Isotope Corporation (OTC PINK: ADMD)
The strategic market sector of ADMD is isotope applications.
Currently, the Company is engaged in the development of RadioGel™,
an Yttrium-90 based brachytherapy device, for the treatment of
tumors. Brachytherapy uses radiation to destroy cancerous tumors by
placing a radioactive isotope inside the treatment area.
The company is engaging the FDA for permission to use RadioGel™
for the treatment of advanced basal and squamous cell skin cancers.
The IsoPet Solutions division of AMI is focused on demonstrating
the safety and therapeutic effectiveness for different animal
cancers in four different university veterinary hospitals. AMI is
positioning itself so that after this demonstration phase, The
Company can begin to generate revenues through the sale of
RadioGel™ to private animal clinics.
The Company currently is outsourcing material aspects of
manufacturing of its product in the United States and intends to
enter into licensing arrangements outside of the United States for
the manufacturing and distribution of RadioGel™ in other
countries.
About RadioGel™ RadioGel™ is a hydrogel liquid containing tiny
Yttrium-90 phosphate particles to be injected into a tumor. This
hydrogel is a liquid at temperatures below body temperature but
begins to gel, harden, upon injection as the temperature increases
to normal body temperature, thereby locking the particles in place.
The particles emit a very high concentrated and contained beta
irradiation to kill the tumor. The beta radiation has a short
penetration distance so there is minimal collateral damage to
healthy tissues outside of the injected area.
RadioGel™ also has a short half-life - delivering more than 90%
of its therapeutic radiation within 10 days. This compares
favorably to other available treatment options requiring up to 6
weeks or more to deliver a full course of radiation therapy. This
is an outpatient treatment much safer to the personnel treating the
patient than competing brands and the patient can go home
immediately with no risk to family members.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
You can identify these statements by the use of the words "may,"
"will," "should," "plans," "expects," "anticipates," "continue,"
"estimates," "projects," "intends," and similar expressions.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those projected or
anticipated. These risks and uncertainties include, but are not
limited to, the Company's ability to successfully execute its
expanded business strategy, including by entering into definitive
agreements with suppliers, commercial partners and customers;
general economic and business conditions, effects of continued
geopolitical unrest and regional conflicts, competition, changes in
technology and methods of marketing, delays in completing various
engineering and manufacturing programs, changes in customer order
patterns, changes in product mix, continued success in technical
advances and delivering technological innovations, shortages in
components, production delays due to performance quality issues
with outsourced components, regulatory requirements and the ability
to meet them, government agency rules and changes, and various
other factors beyond the Company's control.
For more information, please visit www.radiogel.com
Recent presentations and interviews
https://www.redchip.com/company/Biotech/ADMD/376/admd
Company Contact: Michael K. Korenko, Sc.D. President and CEO
Advanced Medical Isotope Corporation MKorenko@isotopeworld.com
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Apr 2024 to May 2024
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From May 2023 to May 2024